Status:

COMPLETED

Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation

Lead Sponsor:

LEO Pharma

Collaborating Sponsors:

Bayer

Conditions:

Healthy

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to determine the dermal sensitization potential of azelaic acid pre-foam formulation.

Detailed Description

In an induction phase a three times weekly exposure over three weeks will be performed, followed by a resting phase. In a following challenge phase single exposure will be performed again and potentia...

Eligibility Criteria

Inclusion

  • healthy volunteers
  • male or female subjects
  • aged 18 - 65 years
  • ability to understand and fulfill the study requirements

Exclusion

  • affected skin in designated test area
  • pregnancy or lactation
  • not willing to comply with study requirements

Key Trial Info

Start Date :

September 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2011

Estimated Enrollment :

240 Patients enrolled

Trial Details

Trial ID

NCT01430533

Start Date

September 1 2011

End Date

December 1 2011

Last Update

April 1 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Robert I. Cooper, MD

Fargo, North Dakota, United States, 58104